Receptor activator of nuclear factor kappa-B (RANK)

Receptor activator of nuclear factor kappa-B (RANK) is a transmembrane protein belonging to the tumor necrosis factor (TNF) receptor superfamily, encoded by the TNFRSF11A gene[1][8]. It acts as the high-affinity receptor for RANKL (receptor activator of nuclear factor kappa-B ligand) and forms a critical signaling axis together with its decoy receptor osteoprotegerin (OPG)[1][3][5]. The RANK/RANKL/OPG pathway centrally regulates osteoclast differentiation, activation, and survival—processes essential for bone remodeling and repair[1][4][5]. RANK is also implicated in immune cell function, lymph node organogenesis, and mammary gland development[1][3]. Dysfunction or mutations in RANK signaling underlie various pathological conditions such as osteoporosis, rheumatoid arthritis, bone metastases in cancer, and rare inherited osteopetrotic disorders[4][5]. Pharmacologically, therapeutic agents like denosumab work by blocking the RANKL–RANK interaction, thereby suppressing osteoclastogenesis and bone resorption, but posing potential risks such as immunosuppression and hypocalcemia[4][6].

Other names

TRANCE receptorTNFRSF11ATumor necrosis factor receptor superfamily member 11A

Inhibition of RANKL-RANK interaction, Blockade of osteoclast activation and formation, Immunomodulation